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The Influence of Vitamin D Metabolism on Gene Expression,
Matrix Production and Mineralization During
Osteoprecursor Cell-Based Bone Development
Shelley S. Masona, b, Sean S. Kohlesa, c, e, Shelley R. Winnc, d, Randy D. Zelicka

and recombinant human bone morphogenetic protein-2 (rhBMP-2)
on the osteoinduction of OPC1.

Abstract
Background: Multipotential precursor cell lines derived from human bone marrow, capable of differentiating into cartilage or bone,
may provide a useful tissue development model for studying the
regulation and metabolism of putative growth and differentiation
factors necessary for tissue regeneration. In mammals, the process
of bone development depends on the proliferation and differentiation of osteoblast lineage cells, and the subsequent synthesis and
mineralization of bone extracellular matrix (ECM). Vitamin D metabolites play a pivotal role in bone and mineral homeostasis, and
are positive factors on bone development. Recently, it was demonstrated that a human-derived engineered osteoblast precursor
cell line (OPC1), derived from human bone marrow, can metabolize the parental precursor vitamin D3 (vitaD3) to the active steroid
1α,25-dihydroxyvitamin D3 (1,25OH2D3), and elicit an osteogenic
response that results in the decrease in proliferation and increase
in ECM synthesis during early bone development. The aim in this
study is to characterize gene expression, matrix production and
mineralization within a bone development model.
Methods: We investigated whether vitaD3 influences bone ECM
mineralization in the same manner as 1,25OH2D3 in confluent cultures of OPC1s. In addition, we explored the influence of vitamin D
metabolites, in combination with other commonly used osteogenic
factors, ascorbic acid, β-glycerophosphate, dexamethasone (dex)
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Results: It was demonstrated that OPC1 expresses the mRNA for
the enzymatic equipment necessary to convert vitaD3 to 1,25OH2D3,
as well as the mRNA expression of the catabolic enzyme known
to regulate the concentration of active 1,25OH2D3. It was also
demonstrated that mRNA expression for the vitamin D receptor
(VDR) was influenced by both vitaD3 and 1,25OH2D3. Differential
results using vitamin D metabolites in combination with ascorbic
acid, β-glycerophosphate, dex and/or rhBMP-2 were observed in
alkaline phosphatase (ALP) activity and calcium deposition, and
mRNA expression of procollagen type I (proColI), osteocalcin
(OC) and osteopontin (OP).
Conclusions: Overall it was demonstrated that vitamin D in combination with osteogenic factors influences the temporal bone development sequence in a positive manner.
Keywords: Cell and tissue engineering; Osteoinduction; Osteogenic factors; Stem cells; Mesenchymal stromal cells; Cholecalciferol;
Calcitriol

Introduction
Most of the load-bearing demand placed on the human body
is transduced by skeletal tissue, and the skeleton’s capacity
to articulate is essential for mobility and locomotion [1].
Consequently, cartilage and bone defects due to trauma, disease and developmental abnormalities may result in severe
disabling pain and immobility for millions of people worldwide [2]. Multipotential precursor cell lines derived from human bone marrow, capable of differentiating into cartilage
or bone, may provide a useful tissue development model for
studying the regulation and metabolism of putative growth
and differentiation factors necessary for tissue regeneration.
There are several factors that need to be taken into consideration for in vitro model systems, such as cell source and
acquisition, phenotypic stability, reproducibility and the incorporation of appropriate signaling molecules. One of the
challenges in using mesenchymal stromal cells (MSCs),
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Table 1. Oligionucleotide Single-Stranded Molecular Primers Used in Quantitative, Real-Time RT-PCR
Primer set

Forward

Reverse

CYP24A1

5’ - GCA GCC TAG TGC AGA TTT - 3’

5’ - ATT CAC CCA GAA CTG TTG - 3’

CYP27A1

5’ - GGC AAG TAC CCA GTA CGG - 3’

5’ - AGC AAA TAG CTT CCA AGG - 3’

CYP27B1

5’ - tgt ttg cat ttg ctc aga - 3’

5’ - CCG GGA GAG CTC ATA CAG - 3’

VDR

5’ - CCA GTT CGT GTG AAT GAT GG - 3’

5’ - GTC GTC GGT GAA GGA - 3’

OC/BGLAP

5’ - CTG GCC ACT GCA TTC TGC - 3’

5’ - AAC GGT GGT GCC ATA GAT GCG - 3’

OP/SPP1

5’ - AAA TAC CCA GAT GTG GC - 3’

5’ - AAC CAC ACT ACC TCG GC - 3’

Pro-ColI

5’ - TGA CGA GAC CAA GAA CTG - 3’

5’ - CCA AAG TCA CCA AAC CTA CC - 3’

or progenitor cells isolated from bone marrow aspirates, is
isolation sufficiency and expansion. This is due to the relatively low frequency at which these cells exist in the marrow stroma (reported to be in the range of 1/10,000 cells to
1/100,000 cells) [1, 3, 4]. In addition, MSCs have a finite
capacity for self-renewal, and the potential to proliferate and
differentiate diminishes with age. MSC isolates also tend to
be heterogeneous, containing progenitor cells with varying
levels of potency. By contrast, the osteoblastic precursor cell
line (OPC1) is a conditionally immortalized cell line derived
from human bone, and has been demonstrated to maintain
phenotypic stability and a consistent pattern of differentiation for more than 70 passages, providing an ideal model for
the study of osteoblast differentiation and bone development
as an alternative to MSCs [5]. We have used the OPC1 in a
previous study and have shown it to provide a consistent and
reproducible culture system for evaluating bone development
[6]. We were able to demonstrate the extra-endocrine metabolism of vitamin D3 (vitaD3) to 1α,25-dihydroxyvitamin
D3 (1,25OH2D3) by OPC1, which resulted in decreased proliferation and increased alkaline phosphatase (ALP) activity
and calcium deposition associated with extracellular matrix
(ECM) bone maturation and mineralization.
In the early 1900s, vitamin D was the fourth identified
essential vitamin, thus named vitamin “D” by convention. It
was not until 50 years later that it was realized that vitamin D
is metabolized and acts as a steroid hormone in an endocrine
manner, a paradigm that has dominated the classic thought
of vitamin D function until the end of the 20th century [7].
Recently, it has been demonstrated that a number of organ
systems are influenced by vitamin D in an autocrine manner, that is, 1,25OH2D3 is being synthesized within those
cells, and/or within adjacent cells (paracrine action). While
the vitamin D endocrine system plays a principal role in the
maintenance of calcium and phosphate homeostasis, extraendocrine metabolism has been postulated to have cellular
functions that include the regulation of proliferation, differ2

entiation and apoptosis in many target tissues [8-11], including bone and cartilage.
VitaD3 is biologically inactive in physiologic concentrations until it is sequentially hydroxylated and the polarity is
increased. VitaD3 is activated by two-sequential hydroxylations, first by the cytochrome P450 oxidase (CYP) 25-hydroxylase, CYP27A1 (mitochondrial) and CYP2R1 (microsomal), resulting in the metabolite 25-hydroxyvitamin D3
(25OHD3), and then to the active metabolite, 1,25OH2D3, by
25-hydroxyvitaminD3-1α-hydroxylase (CYP27B1) [10, 1214].
1,25OH2D3 is the most active form of vitamin D because
of its high affinity for the intranuclear vitamin D receptor
(VDR), mediating its biological influence upon binding.
VDR belongs to the nuclear hormone receptor family and
serves as a ligand-dependent transcription factor (TF) that
controls the expression of vitamin D associated target genes
which include those associated with calcium homeostasis,
cellular proliferation and differentiation, cell division and
cycle arrest, and apoptosis [15-19]. Upon 1,25OH2D3 binding, VDR forms a heterodimer with the retinoid X receptor, which allows it to bind to vitamin D receptor elements
(VDREs) in the promoter regions of target genes [8, 14, 17,
20]. Coupled with other TFs, this complex induces transcription of vitamin D responsive genes including those associated with the CYP-related enzymes required for vitamin D
metabolism [14, 17, 20-22].
The action of vitamin D is limited by the catabolic enzyme 24-hydroxylase (CYP24A1), which results in a compound that is more soluble and has a substantially lower
affinity for VDR [12, 14, 23]. CYP24A1 has been shown
to hydroxylate both 25OHD3 and 1,25OH2D3 to form
24,25OH2D3 and 1,24,25OH3D3, respectively [17]. The main
function of CYP24A1 is to regulate the circulating concentration of 1,25OH2D3 by inactivating it. The catabolic pathway of CYP24A1, collectively known as the C-24 oxidation pathway, starts with the 24-hydroxylation of 25OH2D3
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Figure 1. Temporal alkaline phosphatase activity of OPC1 treated with (A) ethanol vehicle control in standard bone medium (BM-), BM- containing vitamin D3 (BM- vitaD3+) and BM- with 1,25OH2D3 (BM- 1,25OH2D3+); (B) ethanol control
in osteogenic medium (BM+) containing ascorbic acid, β-glycerophosphate and dexamethasone, BM+ containing vitamin
D3 (BM+ vitaD3+), and BM+ with 1,25OH2D3 (BM+ vitaD3+); (C) ethanol control in BM+ containing rhBMP (BMP+), BMP+
containing vitamin D3 (BMP+ vitaD3+), and BMP+ with 1,25OH2D3 (BMP+ vitaD3+). Cellular isolates were collected on day
7, 14 and 21 during the differentiation time course. Treatment with both vitamin D metabolites significantly influenced OPC1
ALP activity in all medium groups (P < 0.01).
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Figure 2. (A) Calcium deposition stained with alizarin red stain (ARS) of OPC1 cultured in BM- and either vitamin D metabolites,
vitamin D3 or 1,25OH2D3. (B) After microscopic analysis, ARS was extracted from each culture well, and quantified on a microplate
reader. By week three of culture, there was a statistically larger amount of calcium deposition detected by ARS in cells treated with
either vitamin D3 or 1,25OH2D3 compared to that of the ethanol control (***P < 0.001).

or 1,25OH2D3 followed by sequential steps of hydroxylation
that lead to the progressive loss of biological activity until
vitamin D is converted to the water-soluble biliary excretory
form, calcitroic acid [10, 12, 24]. 1,25OH2D3 induces and
mediates CYP24A1 via an autocatalytic loop through VDRE
located in the promoter region of the CYP24A1 gene [21].
Generally, basal expression of CYP24A1 is extremely low
but the gene is highly induced by 1,25OH2D3 [11, 20]. Thus,
the synthesis and degradation of 1,25OH2D3 is highly regulated, and the concentration is controlled at the cellular level.
Vitamin D affects many aspects of bone cell biology,
and has been implicated in the regulation of both osteoblastic and osteoclastic activity influencing both resorptive
and synthetic phases of bone remodeling [11]. In addition,
1,25OH2D3 has been demonstrated to regulate osteoblast and
chondrocyte gene transcription, proliferation, differentiation
and ECM maturation [11, 25]. VDR is nearly ubiquitously
expressed, as almost all cells respond to 1,25OH2D3 [26],
and it is known to regulate the function of more than 200
genes [13, 17-19].
In this study, our objective was to quantify the differenti-

4

ation of the OPC1 as an osteoprogenitor along the osteoblastic lineage including the events associated with bone development in the presence of vitamin D metabolites, vitaD3 and
1,25OH2D3. Additional osteogenic factors included ascorbic
acid, β-glycerophosphate, dexamethasone and bone morphogenetic protein-2 (BMP-2). Because in vitro temporal bone
development encompasses three stages (proliferation, bone
ECM maturation and mineralization) and vitamin D has been
shown to significantly hamper OPC1 proliferation [6], confluent cultures were used in order to investigate the influence
on bone ECM maturation and mineralization.

Materials and Methods
Vitamin D and OPC1 cell cultures
VitaD3 (cholecalciferol) and 1,25OH2D3 (calcitriol) were
purchased (Sigma-Aldrich, St. Louis, MO), and maintained
in 10 mM and 10 μM stock solutions in ethanol, respectively.
All other reagents and chemicals were purchased from the
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Figure 3. (A) OPC1 calcium deposition stained with ARS during culture in BM+ and either vitamin D3 or 1,25OH2D3. (B) After
microscopic analysis, ARS was extracted from each culture well and read on a microplate reader. By week three of culture, there
again was a larger amount of calcium deposition detected by ARS in cells treated with either vitamin D3 or 1,25OH2D3 compared to
that of the ethanol control (***P < 0.001). In addition, there was more calcium deposition in the BM+ treatment groups compared
to all BM- groups (shown in Fig. 2).

same vendor unless otherwise indicated. Original OPC1 and
rhBMP-2 were prepared and maintained locally [5].
Cells were cultured at populations of 2.5 × 105 in 75
cm2 tissue culture flasks in alpha modified essential medium
(α-MEM) with 5% fetal bovine serum (FBS). Once confluent, OPCs were plated in 12-well plates after trypsin-ethylenediaminetetraacetic acid (EDTA) enzymatic removal and
counted with 0.4% trypan blue (1:1) on a hemacytometer.
Cultures were then prepared in duplicate at a seeding density
of 3.0 × 104 cells/well in the initial bone medium (designated
as BM-) with 200 mM L-glutamine and antibiotics until 8590% confluent prior to adding experimental medium. Nine
variations of medium were utilized in quadruplicates. BMwith 95% ethanol (EtOH), in an amount that facilitated the
EtOH as a vehicle for vitamin D metabolite delivery, provided a negative control (group 1). The additional groups
included: BM- supplemented with 1 μM vitaD3 (group 2);
BM- supplemented with 10 nM 1,25OH2D3 (group 3); BMsupplemented with osteogenic factors (BM+) comprised of
50 μg/mL ascorbic acid, 10 mM β-glycerophosphate, 10 nM
dexamethasone (dex) and 50 μg/mL of ascorbic acid phos-

phate (Wako Chemical, Osaka, Japan), provided as a positive control (group 4); BM+ supplemented with 1 μM vitaD3
(group 5); and BM+ supplemented with 10 nM 1,25OH2D3
(group 6). Enhanced supplementation groups were also prepared: BM+ supplemented with rhBMP-2 (BMP+) (group
7); BMP+ with 1 μM vitaD3 (group 8); and BMP+ supplemented with 10 nM 1,25OH2D3 (group 9). Fresh medium
was added every 1 to 2 days.
Bone matrix maturation
ALP activity was monitored, as it is known to be involved
with ECM maturation and mineralization through increased
phosphate concentration [27]. ALP levels associated with the
OPC1 response to both vitaD3 and 1,25OH2D3 in BM-, BM+
and BMP+ were determined in duplicate at the previously indicated concentrations. ALP was measured every 7 days. At
the end of the incubation, the cell layers were washed with
cold DPBS and 500 μL 0.1% triton-X in DPBS, then stored
at -80 °C until the end of each experimental period. ALP activity in the cell lysates was measured using ρ-nitrophenyl
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Figure 4. (A) OPC1 calcium deposition as stained with ARS during culture in BMP+ containing rhBMP-2 (BMP+) and either vitamin
D3 or 1,25OH2D3. (B) Quantified ARS as extracted from each culture well and read on a microplate reader. In the second week of
culture, the BMP+ EtOH control had a larger amount of calcium deposition in comparison with the treatment groups (P < 0.05). By
week three of culture, there was more calcium deposition detected by ARS in cells treated with either vitamin D metabolites compared to that of the ethanol control (*P < 0.01). In addition, there was a statistically more calcium deposition in the BMP+ treatment
groups (P < 0.001) compared to all BM- groups (plotted in Fig. 2).

phosphate liquid substrate system at 37 °C for 30 min. Protein content was measured using a micro-volume spectrophometer system (Epoch; Biotek, Winooski, VT).
Bone matrix mineralization
Calcium deposition was determined through a histochemical
analysis of mineralization utilizing Alizarin Red S (ARS).
ARS staining identified calcium-rich deposits made by the
cells in culture. This approach is considered a functional in
vitro endpoint reflecting advanced cell differentiation [28].
Every 7 days the cells were fixed in 10% neutral buffered
formalin for 15 min followed by fixation in 100% cold methanol. Each well was rinsed thoroughly with cold DPBS, and
stained with 40 mM of ARS (pH = 4.1), at room temperature for 20 min with gentle shaking. The cell layers were
rinsed and observed both grossly and microscopically. For
semi-quantification, ARS was extracted from the cells after
incubating for 1 h at room temperature in 10% volume to

6

volume (v/v) acetic acid with gentle shaking, and then the
residual dye was further extracted by scraping the cells and
heating at 85 °C on a heating block with a layer of mineral oil
to prevent evaporation. The samples were neutralized with
10% (v/v) ammonium hydroxide and the extracts were read
at 405 nm on a microplate-reader (Cary 50; Varian Australia
Pty. Ltd). The samples were compared to a serially diluted
ARS standard. The resulting data were normalized with total
protein content measured using a micro-volume spectrophometer system (Epoch; Biotek, Winooski, VT).
Gene sequencing
Quantitative real-time, reverse transcription polymerase
chain reaction (RT-PCR) analysis techniques were used to
characterize the activity of the genes associated with vitamin
D metabolism: CYP24A1, CYP27A1, CYP27B1 and VDR
[16, 29]. In addition, RT-PCR was used to detect levels of
osteopontin (OP), procollagen type I (proColI) and osteocal-
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cin (OC). These noncollagenous and collagenous proteins
are associated with hydroxyapatite binding and pre-collagen
synthesis, respectively, during bone development [5]. The
oligionucleotide RT-PCR primer sequences (Table 1) were
purchased from a commercial source (Intergrated DNA Technologies, Coralville, IA). Briefly, messenger ribonucleic acid
(mRNA) was isolated using 500 μL of a chemical reagent
(TRIzol, Life Technologies, Grand Island, NY) per well of
the 12-well plates. Samples were collected every 7 days and
stored at -80 °C. The mRNA was purified according to the
reagent manufacturer’s specifications and the concentration
was determined in units of μg/mL by spectrophotometric
absorbance of light at wavelengths of 260 nm and 280 nm
(A260/A280) (Epoch, Biotek, Winooski, VT). The complementary deoxyribonucleic acid (cDNA) was synthesized from 2
μg of the mRNA using a high capacity reverse transcriptase
kit (Applied Biosystems, Life Technologies) according to
manufacturer’s instructions. Aliquots of the total cDNA were
amplified in each PCR using fast green master mix (SYBR,
Applied Biosystems, Life Technologies) with the acquired
primers (Table 1). This amplification was performed in a
quantitative thermocycler (Rotor-Gene Q, Qiagen, Germantown, MD) for 45 cycles (30 sec denaturation at 95 °C, 45
sec annealing at 58 °C and 60 sec extension at 72 °C).
Microscopic imaging
Microscopic images were taken using an advanced transmitted light inverted microscope and accompanying software
(EVOS-XL and EVOS3, Advanced Microscopy Group,
Bothell, WA). Images were processed using an open source,
image-processing package (FIJI, ImageJ v1.47d, National
Institutes of Health, Bethesda, MD). To maintain consistency, each image was processed in the same manner including
maintaining consistent light intensities during optical density
measurements. The operations (Contrast-Limited Adaptive
Histogram Equalization commands) included background
subtraction (blocksize 100), mean filter (bin 256) and local
contrast (maximum slope 2.50).
Statistical analysis
Statistical analyses were carried out using commercial software (Prism, Irvine, CA; Excel, Microsoft, Redmond, WA).
Data were expressed as means ± standard error of the mean
(SEM) of samples characterized in three 2-week sample sets
plated in duplicate or quadruplicate, and assayed in duplicate (n = 12 or n = 24, respectively). A two-way analysis of
co-variance (ANCOVA) with a Bonferonni post-test (direct
comparison with controls), Dunnett’s test (pairwise comparisons) and non-linear regression (polynomial quadratic
function) were applied to statistically compare the treatment
groups over time, with asterisks of *P < 0.05, **P < 0.01, and
***P < 0.001 indicating varying levels of statistical signifi-
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cance as noted in the figures.

Results
Increased ALP activity is known to be associated with osteoblast function and the matrix maturation stage of bone
development. ALP activity here was found to be statistically
higher (P < 0.01) in groups cultured in standard bone medium (BM-) containing vitaD3 by week two of culture, and
significantly higher (P < 0.001) in groups containing either
vitaD3 or 1,25OH2D3 by week three compared to the BMethanol vehicle control (Fig. 1A). For groups in osteogenic
medium (BM+) both vitamin D metabolites displayed statistically higher (P < 0.001) ALP activity compared to the BM+
EtOH control in both the second and third week (Fig. 1B).
All groups cultured in BM+ were significantly higher (P <
0.001) than the groups cultured in BM- during the 3-week
culture period, and reached maximal ALP, while groups in
BM- did not reach maximal ALP activity. Groups cultured
in BM+ containing rhBMP (BMP+) showed a significant increase (P < 0.001) only in the second week compared to the
BMP+ EtOH control, and by week three all groups displayed
low levels of ALP activity (Fig. 1C). While groups cultured
in BM+ continued to increase in ALP activity throughout
the 3-week culture period, BM+ reached a peak in between
weeks 1 and 3, and began to decline in between weeks 2 and
3.
The primary function of osteoblasts is to produce and
maintain mineralized ECM. For our samples cultured in
BM- with or without vitamin D metabolites, vitaD3 and
1,25OH2D3, calcium deposition was significantly greater (P <
0.001) in cultures containing either of the vitamin D metabolites compared with the BM- ethanol control (Fig. 2). OPC1
cultured in BM+ with or without the vitamin D metabolites
showed a significantly higher amount of calcium deposition
(P < 0.001) throughout the 3-week culture period compared
to that of cultures in BM-. Cultures containing either vitaD3
or 1,25OH2D3 were significantly higher (P < 0.001) than
the BM+ EtOH control by the third week of culture (Fig.
3). Cultures containing rhBMP (BMP+) showed a statistically significant amount of calcium deposition (P < 0.001)
compared to that of the groups cultured in BM- throughout
the 3-week culture period. The presence of vitaD3 in BMP+
medium caused a larger amount of calcium deposition (P
< 0.01) compared to that of the BMP+ EtOH control, and
slightly more deposition (P < 0.05) when in the presence of
1,25OH2D3 (Fig. 4).
As mentioned, CYP27A1 and CYP27B1 are hydroxylases demonstrated to be involved in the metabolism of
vitaD3 to 25OHD3, and convert 25OHD3 to 1,25OH2D3, respectively. Here, OPC1 expressed both CYP27A1 (Fig. 5A)
and CYP27B1 (Fig. 5B) in response to the presence of vitaD3, relative to the BM- EtOH control. Increases in both
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Figure 5. Induced mRNA expression of (A) CYP27A1, (B) CYP27B1, (C) CYP24A1 and (D) VDR in nine treatment group cultures
of OPC1s including either vitamin D3 or 1,25OH2D3 in standard bone medium (BM-) and medium containing osteogenic factors
(BM+ and BMP+). Total RNA was isolated and examined by quantitative RT-PCR. Data were normalized by the level of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a protein-coding gene. The figure legend for (A) applies to Fig. 5 and 6 where the
bars (front to back) are associated with the listed experimental groups (top to bottom).

hydroxylases occurred in some of the treatment within the
first 72 h of treatment (treatment added on day 4 of culture)
as measured at week one, but decreased dramatically by the
second week in the continuous presence of vitaD3. In the
8

groups containing osteogenic factors (BM+ and BMP+), the
expression of CYP27A1 was higher then in the BM- group
treated with vitaD3. However, in groups treated with BMP+,
CYP27B1 expression was lower then in the BM- and BM+
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Figure 6. Induced mRNA expression of (A) proColI, (B) OP and (C) OC in nine treatment group OPC1 cultures containing the vitamin
D metabolites and/or osteogenic factors (see the figure legend for Fig. 5A). Total RNA was isolated and examined by quantitative RTPCR and data were again normalized by levels of GAPDH.

groups treated with vitaD3. OPC1 also expressed CYP24A1
and VDR mRNA in response to vitaD3 and 1,25OH2D3 (Fig.
5C, D). In the first week, all groups treated with the vitamin
D metabolites had significant increases (P < 0.001) in both
CYP24A1 and VDR expression relative to the BM- control.
BM- cultures treated with vitaD3 expressed a much higher
amount of CYP24A1 mRNA relative to BM- control, compared to the cultures containing osteogenic factors. After the
continuous presence of vitaD3, in the second week of culture,
CYP24A1 expression decreased for the BM- groups, but increased in groups containing BM+ and BMP+. All groups
treated with vitaD3 and 1,25OH2D3 had statistically more
VDR mRNA expression (P < 0.001) relative to the BM- control during the first week of culture, but which decreased by
the second week.
Synthesis of procollagen type I (proColI) is known to
precede the production of collagen type I (ColI), a major
component of bone ECM. This synthesis is enhanced during
early osteoblast differentiation, while OC and OP are associated with later stages of osteoblast differentiation and bone
development. Real-time PCR analysis showed a significant
increase in proColI mRNA expression (P < 0.001) during
the first week of OPC1 culture in all groups relative to the
BM- control, and a higher increase with treatment groups
containing either vitaD3 or 1,25OH2D3 (Fig. 6A). There was
no statistically significant expression of proColI mRNA in
the second week in any of the culture groups (P > 0.05). In
contrast to the expression of proColI, OP mRNA expression
was not seen in the first week of culture time in any of the
groups and increased in both the second and third week of

culture relative to the BM- control (Fig. 6B). The BMP+
control without vitamin D displayed the highest OP mRNA
expression relative to the BM- control. Similar to OP mRNA
expression, expression of OC mRNA was highest in the
BMP+ control group, but was increased in all groups relative to the BM- control (Fig. 6C). However, in contrast to OP
mRNA expression, OC mRNA expression was increased in
the first week, and continued to increase during the 3-week
culture period.

Discussion
In this study, an engineered OPC1 was used to examine
the effect of vitamin D metabolites, vitaD3 and 1,25OH2D3,
on the maturation and mineralization of culture-expanded
cells as a model for bone development. In comparison to
the untreated cells, vitamin D metabolites in combination
with ascorbic acid, β-glycerophosphate, dex and/or BMP2, produced more calcium deposition and showed a greater
increase in ALP over time. Cultures containing osteogenic
factors varied in ALP activity depending on the presence of
rhBMP-2. In addition to ALP activity and calcium deposition, mRNA expression of proColI, OC and OP were analyzed over the 3-week culture period, as well as the mRNA
expression of genes associated with vitamin D action and
metabolism.
Osteoblasts are bone-forming cells derived from multipotential progenitor cells within the bone marrow stroma
that also are capable of committing to other mesenchymal
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lineages, including fibroblasts, myoblasts, chondrocytes,
adipocytes and osteoblasts [3, 30]. Once precursors have
committed to a specific lineage, tissue specific molecules
are expressed. Phenotypical characteristics of an osteoblast
include the synthesis and mRNA expression of proColI preceding ColI, OC, OP, VDR, increased ALP activity and the
ability to mineralize ECM. When osteoblast precursors commit to the osteoblastic lineage, the osteoblasts express bone
matrix protein genes at different expression levels depending
on the maturation level of the cells [31]. For example, immature mesenchymal cells and preosteoblasts weakly express
ColI and collagen type II (ColII), while immature osteoblasts
express OP, and bone sialoprotein (BSP), a component of
mineralized tissues. Mature osteoblasts meanwhile strongly express OC [31] and may eventually become osteocytes
when they are embedded into the bone matrix and express
dentin matrix protein 1 (DMP-1).
In vitro human osteoblasts respond to exogenous
1,25OH2D3 by decreasing their rate of proliferation while
increasing their expression of mRNA of osteogenic biomarkers such as OC and OP. While it has been known that
circulating vitamin D is derived from the kidneys, recently a
number of studies have demonstrated the extra-renal synthesis of 1,25OH2D3 from 25OHD3 in skin, liver, lymph nodes,
activated monocytes/macrophages, dendritic cells and osteoblasts [11]. In contrast to extra-renal metabolism of 25OHD3
to 1,25OH2D3, there have been occasional reports of extrahepatic metabolism of vitaD3, but no detailed analysis until
now. Recently, we demonstrated that OPC1 could metabolize vitaD3 to 1,25OH2D3 in a dose-dependent manner [6],
and in this present experiment, we were able to demonstrate
the upregulation of mRNA expression of vitamin D associated hydroxylases CYP27A1, CYP27B1 and CYP24A1, as
well as VDR in response to vitaD3. It was also demonstrated
that vitaD3 influenced the expression of osteogenic mRNA
proColI, OC and OP in the same manner as 1,25OH2D3.
In addition to the effects of vitamin D metabolites on
OPC1, vitamin D in combination with common osteogenic
factors was investigated. It was demonstrated that in combination with these osteogenic factors, matrix maturation
and mineralization were significantly increased. However,
there were differential results in bone maturation associated with ALP activity seen in cultures treated with BMP+.
ALP expression is associated with bone cell phenotype, and
in heavily mineralized cultures, cellular levels of ALP decline [32]. OPC1 cultured in BMP+ with or without vitamin
D metabolites demonstrated an increase in mineralization,
and consequently with the mRNA expression of OC and OP,
proteins that are known to increase with the accumulation
of mineralization, compared to the BM- and BM+ groups.
These results indicate that rhBMP-2 had a major influence
on OPC1 bone mineralization, that may exceed the influence of vitamin D. A major limitation to this result, was that
BMP+ cultures were so heavily mineralized that by day 17
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of culture time, the monolayer began to detach from the culture vessel.
It has been previously demonstrated that using dex,
BMP-2 and 1,25OH2D3 tend to enhance a more differentiated osteoblast phenotype [33]. However in our study, OP
and OC mRNA expression in groups treated with vitaD3 or
1,25OH2D3 and BMP+ was slightly lower than the BMP+
control, but higher than the osteogenic medium containing
vitamin D metabolites and no BMP (BM+). This may be because we used a higher dose of 1,25OH2D3, which would
also explain the very significant increase in catabolic enzyme
mRNA expression of CYP24A1 seen in the second week of
culture. In addition, it could be postulated that as a regulator
of ECM mineralization, vitamin D dampened the effects of
BMP. Many in vitro vitamin D studies investigating the antiproliferative and pro-differentiative effects of vitamin D are
short-term and use a supra-physiological dose; however, for
long-term cultures using vitamin D as an osteognenic factor,
it may be beneficial to use a dose that more closely resembles
the phsyiological dose.
It has been long recognized that long-term or excessive use of glucocorticoids (GC), whether from endogenous
hypersecretion or iatrogenically, manifests adverse skeletal
effects such as osteoporosis [34]. In human subjects receiving long-term GC treatment, bone loss is associated with
the decrease in overall bone formation rate and in the mean
thickness of the walls on newly synthesized trabecular bone,
a pattern consistent with the decrease in number and/or activity of osteoblasts rather than the increase in number and/
or activity of osteoblasts [34]. Paradoxically, several studies
have demonstrated that treating cells derived from human
bone with GCs promotes osteogenic differentiation, and has
been proposed as a standard supplement for the ex vivo expansion of cells with osteogenic potential for use in tissue
reconstruction and repair [34]. Dexamethasone is a GC that
is commonly used as an inducer of bone marrow stromal cell
differentiation, which reliably stimulates the development of
many, but not all, phenotypic features of human osteoblasts
[33]. However, GCs have deleterious effects in vivo, resulting in inhibition of osteoblast function. BMP-2 is another
inducer of osteoblast differentiation, and is essential for
postnatal bone formation. BMP-2 has been used to induce
osteoblast differentiation in vitro in many human and animal
models, and is believed to provide a more physiologic stimulus than dexamethasone; however, it appears to enhance a
more mature osteoblast characteristic [33].
Overall, this work provided baseline two-dimensional
culture data characterizing the interaction between vitamin
D metabolites and an osteoprecursor cell line. Ongoing efforts are expanding this approach into a tissue engineered
model created with three-dimensional culture and custom
biomaterial scaffolds including the application of mechanical
stimulation through access to a novel bioreactor [2]. In addition, the combined influence of vitamin D and biomechanics
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on isolated single cells within an optofluidic environment is
concurrently being investigated. This active research theme
addresses multiscale mechanotransduction through novel
bioengineering approaches.
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